AI
JAZZ icon

Axiom Investors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Axiom Investors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-133,865
Closed -$23.1M – 142
2015
Q1 		$23.1M Buy
133,865
+24,190
+22% +$4.15M 0.63% 53
2014
Q4 		$18M Sell
109,675
-72,245
-40% -$12M 0.44% 65
2014
Q3 		$29.2M Sell
181,920
-244,538
-57% -$37.6M 0.72% 58
2014
Q2 		$62.7M Buy
426,458
+27,992
+7% +$3.88M 1.48% 25
2014
Q1 		$55.3M Buy
398,466
+4,266
+1% +$642K 1.32% 27
2013
Q4 		$49.9M Sell
394,200
-13,140
-3% -$1.36M 1.33% 25
2013
Q3 		$37.5M Sell
407,340
-25,950
-6% -$2.09M 1.2% 40
2013
Q2 		$29.8M Buy
+433,290
New +$26.5M 1.08% 46

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Axiom Investors's JAZZ Position: Q2 2015 in Review

Axiom Investors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2015, closing a stake of 133,865 shares — an estimated $23.1M sold.

Axiom Investors first reported a position in JAZZ in Q2 2013 and held it in 8 quarters. The position peaked at $62.7M in Q2 2014. 373 funds tracked by Wall St. Rank hold JAZZ as of Q2 2015.

  • Axiom Investors reported no remaining Jazz Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Axiom Investors sold 133,865 Jazz Pharmaceuticals shares in Q2 2015, an estimated $23.1M.
  • Axiom Investors first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • Axiom Investors's Jazz Pharmaceuticals position peaked at $62.7M in Q2 2014.
  • 373 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2015.

Based on Axiom Investors's 13F filing for Q2 2015, filed 13 Aug 2015.